TA-65 lengthens telomeres in a double-blind, placebo-controlled, randomized trial
Compared with the placebo group and assuming 100 base pair erosion per year, we can say that the low-dose TA-65 group GAINED SEVEN YEARS of viable telomere length.
Compared with the placebo group and assuming 100 base pair erosion per year, we can say that the low-dose TA-65 group GAINED SEVEN YEARS of viable telomere length.
Yesterday, we lost a great soul when Stein Erickson, Norwegian Olympian and Johnny Appleseed of Skiing in America passed away of “natural causes” at age 88.
So we suspected that chronic CMV infection ages us but we only conprehended that the immune system burns out fighting it. Until this paper, we didn’t realize that it also steals the healthy gene transciption factors that the host cell needs to stabilize its telomers. It’s a double whammy.
DISCLAIMER: This website is for educational purposes only and is not for advertising. Telomerase activators and nanovesicles are not FDA-approved to prevent or treat any disease and anecdotes are not scientific proof of efficacy. All patients were treated in the context of a fully informed and legally-protected patient physician relationship.
Required fields
© 2020 Recharge Biomedical
Exosomes and TA-65 are not FDA-approved to prevent or treat any illness